What Nurix Therapeutics stock’s recent move may be telling you

Nurix Therapeutics (NRIX) has caught investor attention after a recent share price move, prompting a closer look at how its clinical stage pipeline, revenue profile, and market performance currently line up.

Nurix Therapeutics’ recent 1 day share price return of 1.47% comes after a mixed few months, with the year to date share price return down 8.53% but the 1 year total shareholder return at 62.28% suggesting longer term momentum has been stronger than the shorter term price swings.

If this kind of move has you looking beyond a single biotech, it could be a useful moment to scan other healthcare focused opportunities through 34 healthcare AI stocks

With Nurix Therapeutics reporting US$71.8 million in revenue, a reported loss of US$295.3 million, and the stock trading at a discount to analyst targets, the key question is whether this presents a buying opportunity or if the market already prices in future growth.

Preferred Price-to-Sales Multiple of 23.8x: Is it justified?

On a P/S basis, Nurix Therapeutics looks expensive against many peers, with the stock trading at a 23.8x multiple despite its current loss making profile.

The P/S ratio compares the company’s market value with its revenue. This can be a common yardstick for early stage biopharma where earnings are still negative. A higher P/S often reflects the market’s willingness to pay up for expected future revenue, especially when the pipeline and growth outlook are central to the story.

For Nurix Therapeutics, analysts expect revenue to grow around 42.2% per year. The P/S of 23.8x is lower than the peer average of 29x cited in the data, but higher than the wider US Biotechs industry average of 10.3x. At the same time, the estimated fair P/S ratio in the dataset is effectively at 0x, which implies a very large gap between where the multiple currently sits and a level the regression based fair ratio could move toward.

Result: Price-to-Sales of 23.8x (OVERVALUED)

However, the loss of US$295.3 million and reliance on early stage clinical programs mean that setbacks in trials or funding conditions could quickly challenge today’s rich P/S multiple.

Next Steps

The mix of potential rewards and clear risks around Nurix Therapeutics can leave sentiment feeling finely balanced, so do not wait to review the underlying data and decide where you stand based on 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop at a single stock when there are focused sets of ideas already lined up. Use these curated lists to pressure test and expand your watchlist.

• Target potential mispricings by scanning companies that combine quality fundamentals with appealing valuations through the 49 high quality undervalued stocks.
• Build a steadier income stream by reviewing companies offering higher yields and resilient payouts inside the 12 dividend fortresses.
• Guard your capital by focusing on companies with stronger financial footing and robust balance sheets using the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.